logo
Share SHARE
FONT-SIZE Plus   Neg

Foundation Medicine And Clovis Oncology Enter Into Diagnostic Collaboration

Foundation Medicine Inc. and Clovis Oncology Inc. (CLVS) announced that they have entered into a diagnostic collaboration. The company said that the goal of the collaboration is to develop an in-vitro diagnostic or IVD to identify biomarkers to select cancer patients most likely to respond to Clovis' product candidate rucaparib, a poly (ADP-ribose) polymerase or PARP inhibitor currently in Phase I/II clinical development.

Clovis Oncology said that the company and Foundation Medicine will analyze the genomic alterations found in tissue samples from patients to evaluate the feasibility of developing an IVD method to identify patients who have tumors more likely to respond to rucaparib.

In particular, the goal of the collaboration is to identify the additional genetic mutations beyond those in germ-line and somatic BRCA that are associated with defective DNA repair and may define appropriate tumor targets for rucaparib.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Taco Bell, a division of Yum! Brands Inc, is planning to test delivery of food items on college campuses, the Street reported. The move comes at a time the fast food chain seeks to leverage demand for its popular breakfast and dinner items. In an unusual incident, an Airbus operated by Singapore Airlines temporarily lost power on both its Rolls Royce engines during a flight and plunged almost 13,000 feet or 3.96 kilometers. However, pilots managed to save the Airbus through standard operational procedures and it continued on its routine path. Hormel Foods has agreed to buy organic meat products maker Applegate Farms LLC for about $775 million, as consumers increasingly use natural and organic foods in their diet.
comments powered by Disqus
RELATED NEWS
Trade CLVS now with 
Follow RTT